REGN · News · 20261112N

Product / Drug Pipeline Progress

REGENERON PHARMACEUTICALS, INC. · 2026-11-12 · Importance 31 · Surprise 42

Regeneron reported first-in-human results for CIDEBsiRNA, an investigational liver-targeted siRNA for metabolic dysfunction-associated steatotic liver disease (MASLD). A single dose reduced liver fat by 58%–80%, with reductions sustained through 36 weeks; 62% of treated participants achieved normal liver fat levels, compared with none in the placebo group. The study also showed improvements in liver injury markers, and the results were presented at AASLD and published in The New England Journal of Medicine.

Key facts